Tesamorelin vs CJC-1295 without DAC

Both are stabilised GHRH analogues. Tesamorelin is full-length GHRH with an N-terminal modification and has phase 3 data and US approval for HIV-associated abdominal fat; Mod GRF 1-29 is a shorter research analogue with no approval.

HPLC tested · JanoshikJanoshik CertificatesNationwide DeliveryResearch Only

Tesamorelin

Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH).

BEST STUDIED FOR

GHRH-analogue and visceral-fat research

R1 199View product →

🧪

CJC-1295 without DAC

A stabilised 29-amino-acid GHRH fragment with four amino-acid substitutions — the short-acting cousin of CJC-1295 with DAC.

BEST STUDIED FOR

GH secretagogues

Read the cited profile →

Side by side · to buy

Price, purity and dispatch

Compare	Tesamorelin10 mg · more sizes	CJC-1295 without DAC
Price	fromR1,199	—
Cost per mg	R120 / mg	—
Purity (Janoshik)	On request	—
Stock	Restocking	—
Dispatch	When restocked	—
Certificate	Request CoA	—
Literature	3 papers →	3 papers
Research focus	GHRH-analogue and visceral-fat research	GH secretagogues
	Notify me	Read the cited profile

Prices are read live from the catalogue. Cost per mg is the vial price over its stated mg. Purity is shown only where the certificate is published. Every compound is supplied for laboratory research only.

SIDE BY SIDE

	Tesamorelin	CJC-1295 without DAC
The key difference	Approved, trans-3-hexenoyl-modified GHRH(1-44)	Unapproved, substituted GHRH(1-29)
Class	GH secretagogues	GH secretagogues
Mechanism	Tesamorelin is a stabilised synthetic analogue of growth-hormone-releasing hormone (GHRH).	GHRH(1-29)-NH2 is the shortest fully active portion of GHRH.
Status	An approved medicine (US) for excess abdominal fat in HIV-associated lipodystrophy; research use elsewhere.	GHRH(1-29) analogues were studied clinically from the 1980s (GH secretion, paediatric growth). The modified version circulates as a research peptide and has been found in seized doping material.
Reported safety signals	Label-level trial data exist for its approved indication, including IGF-1 elevation and injection-site effects.	Older GHRH(1-29) studies reported short-term tolerability; GHRH analogues are prohibited in sport.
A key study	A pooled analysis of two phase-3 trials reported that tesamorelin reduced visceral adipose tissue in HIV patients with excess abdominal fat. (J Clin Endocrinol Metab 2010, PMID 20554713)	Measured GH responses to GHRH(1-29)-NH2 and a D-Ala2-substituted analogue in normal men across a dose range. (Peptides 1985, PMID 2866496)

WHEN TO RESEARCH WHICH

Tesamorelin offers the clinical dataset; Mod GRF 1-29 is the common short-acting research analogue. Both are discussed here strictly as research compounds; nothing on this page is medical advice or a dosing guide.

REFERENCES (PUBMED)

[Tesamorelin] Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials — J Clin Endocrinol Metab 2010. PMID 20554713
[Tesamorelin] Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial — JAMA 2014. PMID 25038357
[Tesamorelin] Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension — J Acquir Immune Defic Syndr 2010. PMID 20101189
[CJC-1295 without DAC] Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men — Peptides 1985. PMID 2866496
[CJC-1295 without DAC] Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies — J Med Chem 1998. PMID 9513600
[CJC-1295 without DAC] Glycine-modified growth hormone secretagogues identified in seized doping material — Drug Test Anal 2019. PMID 30136411

FREQUENTLY ASKED

What is the difference between Tesamorelin and CJC-1295 without DAC?

What is the regulatory status of Tesamorelin and CJC-1295 without DAC?

Tesamorelin: An approved medicine (US) for excess abdominal fat in HIV-associated lipodystrophy; research use elsewhere. CJC-1295 without DAC: GHRH(1-29) analogues were studied clinically from the 1980s (GH secretion, paediatric growth). The modified version circulates as a research peptide and has been found in seized doping material.

What safety signals have been reported?

Tesamorelin: Label-level trial data exist for its approved indication, including IGF-1 elevation and injection-site effects. CJC-1295 without DAC: Older GHRH(1-29) studies reported short-term tolerability; GHRH analogues are prohibited in sport.

Which studies is this comparison based on?

For Tesamorelin: “Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials” (PMID 20554713); “Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial” (PMID 25038357); “Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension” (PMID 20101189). For CJC-1295 without DAC: “Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men” (PMID 2866496); “Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies” (PMID 9513600); “Glycine-modified growth hormone secretagogues identified in seized doping material” (PMID 30136411).